

Wheelchair mounted robotic arm – Kinova Jaco2

Clinical Policy ID: CCP.1520

Recent review date: 8/2025

Next review date: 12/2026

Policy contains: Kinova Jaco2, robotic arm.

AmeriHealth Caritas VIP Care has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas VIP Care's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered, on a case by case basis, by AmeriHealth Caritas VIP Care when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas VIP Care's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas VIP Care's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas VIP Care will update its clinical policies as necessary. AmeriHealth Caritas VIP Care's clinical policies are not guarantees of payment.

Coverage policy

The wheelchair-mounted Kinova Jaco2 robotic arm is investigational/not clinically proven and, therefore, not medically necessary.

Limitations

No limitations were identified during the writing of this policy.

Alternative covered services

Standard wheelchairs.

Background

Since about 2000, robotic arms have been developed to assist patients with upper extremity disorders in completing activities of daily living. Several of these are now commercially available. By 2016, more than 200 units had been sold in more than 25 countries (Campeau-Lecours, 2016). However, many robotic arms use joysticks for control, which only allows patients to perform daily activities on a limited basis (Arif, 2022).

One advanced assisted arm is the Kinova Jaco2, first offered by Kinova, Inc. (Broisbriand, Quebec, Canada) in 2008 (Routhier, 2014). This model is a wheelchair-mounted robotic device weighing 3 kg. The arm is composed of six interlinked segments (corresponding to shoulder, elbow, and wrist), including a three-fingered hand. A joystick or other control interface (e.g., sip and puff, head control, head array) allows the user to move the robot's hand in three-dimensional space. The user can also modify the orientation of the hand, along with controlling gripping by opening and closing the hand with two or three fingers. An external button may be used to switch between modes of control (Routhier, 2014; Sauzin, 2017).

Tasks such as pushing an elevator button or eating require the user to toggle through multiple modes and access multiple motion commands. The Kinova Jaco2 allows the presetting of positions and trajectories to optimize time and effort needed to complete the task (Campeau-Lecours, 2016).

The Kinova Jaco2 allows the patient more control with normal activities; decreases reliance on others while encouraging self-empowerment; and can lead to improved safety. It is intended for people with disabilities who have limited mobility in their arms and upper extremities and are able physically and cognitively to safely and independently control a motorized wheelchair through a joystick, head-mounted control, or other technological controls (Kinova Robotics, 2024)

The U.S. Food and Drug Administration announced a Class I recall, the most serious designation, in August 2024, for the KINOVA Jaco assistive robotic arm. This recall affected 949 units across five model numbers that were distributed worldwide. The recall was prompted by a safety risk where a damaged Jaco arm could create a fire hazard if it came into contact with a wheelchair with electrical leakage. The recall's designation remained open by the FDA as of July 2025 (U.S. Food and Drug Administration, 2025).

Findings

Guidelines

No guidelines from professional medical societies specifically mention the Kinova Jaco2 robotic arm.

Evidence review

The evidence consists of small case series of mobility and user satisfaction with the Jaco robotic arm. An early study of the Jaco robotic arm (n = 31) showed most participants could accomplish tasks on their first attempt, and that caregiving time could be reduced by 41% (Maheu, 2011).

A study (n = 14) of persons with upper body disabilities using the Jaco robotic arm found a reduction of 72% in time needed to perform activities, along with improvements of 2.3 and 2.9 on a seven-point Likert scale for perceived ease of use and usability, respectively. Authors conclude that Jaco could produce significant improvements in performing activities of daily living (LeBrasseur, 2021).

A study (n = 7) found that upper extremity performance to accomplish certain life habits improved after long-term use with Jaco. Authors determined satisfaction among users was high, psychosocial impacts were positive, and impacts on family caregivers were slight (Beaudoin, 2019). The same research team had assessed 36 studies of robotic arms (Kinova Jaco and others) in terms of self-care, productivity, and leisure, finding mostly positive impacts (mean quality score 8.8 of 15) (Beaudoin, 2018).

A survey found 31% (n = 29) of 93 occupational therapists had recommended wheelchair-mounted robotic arms; of these, 26 of 29 were the Jaco robotic arm. Barriers to recommendations commonly cited include limited funding, lack of training and knowledge, and resource constraints (Bourassa, 2023).

Interviews with Kinova Jaco users identified use of the joystick to be a key problem in terms of time and cognitive load. Mode switching was a particular problem, consuming 17.4% of execution time for able-bodied users controlling the Jaco (Herlant, 2016).

Laser pointer interactions, allowing wheelchair-bound patients with upper body disabilities to point out objects and pick them up, were the subject of experiments using a Kinova Jaco robotic arm. Average time consumption of the pose generation was reduced from 5.36 to 4.43 seconds, and synchronously, the pose estimation error was reduced from 21.31% to 3.91% (Zhong, 2019). A review showed the rate that a laser pointer correctly selected the desired object ranged from 92% to 99% (Liu, 2023).

In 2024, we found no newly published relevant literature to add to the policy. No policy changes are warranted.

In 2025, we found that peer-reviewed literature on wheelchair-mounted robotic arms focused on usability and patient satisfaction rather than clinical outcomes like functional independence measures, reduced caregiver hours, pressure injury rates, or health-related quality-of-life scores. Spittel (2024) studied recipients with amyotrophic lateral sclerosis: 10/14 (71%) used devices daily with a Net Promoter Score of +57, though 53/85 (62%) interested patients never obtained devices due to cost, technical unsuitability, or death during the 196-229 day procurement process. Hutmacher (2025) surveyed individuals with tetraplegia (n = 49): 37/49 (76%) anticipated greater independence from robotic arms and 28/49 (57%) preferred voice control, while 22/49 (45%) cited lack of information and 13/49 (26%) cited purchase cost as main barriers. No policy changes warranted.

References

On July 18, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “Kinova Jaco2” and “robotic arm.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Arif Z, Fu Y. Mix frame visual servo control framework for autonomous assistive robotic arms. *Sensors (Basel)*. 2022;22(2):642. Doi: 10.3390/s22020642.

Beaudoin M, Lettre J, Routhier F, Archambault PS, Lemay M, G  linas I. Impacts of robotic arm use on individuals with upper extremity disabilities: A scoping review. *Can J Occup Ther*. 2018;85(5):397-407. Doi: 10.1177/0008417418820878.

Beaudoin M, Lettre J, Routhier F, Archambault PS, Lemay M, G  linas I. Long-term use of the JACO robotic arm: A case series. *Disabil Rehabil Assist Technol*. 2019;14(3):267-275. Doi: 10.1080/17483107.2018.1428692.

Bourassa J, Faieta J, Bouffard J, Routhier F. Wheelchair-mounted robotic arms: A survey of occupational therapists' practices and perspectives. *Disabil Rehabil Assist Technol*. 2023;18(8):1-10. Doi: 10.1080/17483107.2021.2017030.

Campeau-Lecours A, Maheu V, Lepage S, Lamontagne H, Latour S, Paquet L, Hardie N. JACO assistive robotic device: Empowering people with disabilities through innovative algorithms. https://www.resna.org/sites/default/files/conference/2016/other/campeau_lecours.html. Published 2016. Herlant

LV, Holladay RM, Srinivasa SS. Assistive teleoperation of robot arms via automatic time-optimal mode switching. *Proc ACM SIGCHI*. 2016;35:42. Doi: 10.1109/HRI.2016.7451731.

Hutmacher N, Bellwald A, Rätz R, et al. Identification of needs for an assistive robotic arm in individuals with tetraplegia: a mixed-methods approach. *J Neuroeng Rehabil*. 2025;22(1):113. Doi:10.1186/s12984-025-01642-8.

Kinova Robotics. Robotic arm: Enabling new possibilities. <https://assistive.kinovarobotics.com/product/jaco-robotic-arm>. Published 2024.

Lebrasseur A, Lettre J, Routhier F, Archambault PS, Campeau-Lecours A. Assistive robotic arm: Evaluation of the performance of intelligent algorithms. *Assist Technol*. 2021;33(2):95-104. Doi: 10.1080/10400435.2019.1601649.

Liu Y, Liu Y, Yao Y, Zhong M. Object affordance-based implicit interaction for wheelchair-mounted robotic arm using a laser pointer. *Sensors (Basel)*. 2023;23(9):4477. Doi: 10.3390/s23094477.

Maheu V, Frappier J, Archambault PS, Routhier F. Evaluation of the JACO robotic arm: Clinico-economic study for powered wheelchair users with upper-extremity disabilities. *IEEE Int Conf Rehabil Robot*. 2011;2011:5975397. Doi:10.1109/ICORR.2011.5975397.

Routhier F, Archambault P, Cyr M-C, Maheu V, Lemay M, Gélinas I. Benefits of JACO robotic arm on independent living and social participation: An exploratory study. *Rehabilitation Engineering and Assistive Technology Society of North America*. <https://www.resna.org/sites/default/files/conference/2014/PDF%20Versions/Robotics/Routhier.pdf>. Published 2014.

Sauzin D, Vigouroux N, Vella F. Usability of JACO arm interfaces designed with a user-centred design method. *Stud Health Technol Inform*. 2017;242:573-582. <https://pubmed.ncbi.nlm.nih.gov/28873855/>.

Spittel S, Meyer T, Weyen U, et al. User expectations and experiences of an assistive robotic arm in amyotrophic lateral sclerosis: a multicenter observational study. *Neurol Res Pract*. 2024;6(1):42. Doi:10.1186/s42466-024-00342-3,

U.S. Food and Drug Administration. Class 1 device recall JACO. Updated July 18, 2025. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=209236>

Zhong M, Zhang Y, Yang X, et al. Assistive grasping based on laser-point detection with application to wheelchair-mounted robotic arms. *Sensors (Basel)*. 2019;19(2):303. Doi: 10.3390/s19020303.

Policy updates

8/2022: initial review date and clinical policy effective date: 9/2022

8/2023: Policy references updated.

8/2024: Policy references updated.

8/2025: Policy references updated.